Find Inclisiran manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

API Reference Price

read-more
read-more
[{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1736101800,"product":"INCLISIRAN INCLISIRAN","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"SHANGHAI AURISCO BIOTECH CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.10","actualQuantity":"100","unit":"GMS","unitRateFc":"1302","totalValueFC":"130759.9","currency":"USD","unitRateINR":"112753.2","date":"06-Jan-2025","totalValueINR":"11275320","totalValueInUsd":"130759.9","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"7642182","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"ROOM 1101, BUILDING A, NO.58, TANZHU ROAD, SHANGHAI CHINA","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1745951400,"product":"INCLISIRAN SODIUM (LIST 4 SR.NO.148) INCLISIRAN SODIUM (LIST 4 SR.NO.148)","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"SHANGHAI AURISCO BIOTECH COLTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.87","actualQuantity":"871.9","unit":"GMS","unitRateFc":"500","totalValueFC":"440015.1","currency":"USD","unitRateINR":"43200","date":"30-Apr-2025","totalValueINR":"37666080","totalValueInUsd":"440015.1","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"9799749","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"ROOM 1101, BUILDING A, NO.58,TANZHU ROAD, SHANGHAI, SDNF CHINA","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1747765800,"product":"INCLISIRAN SODIUM (LIST 4 SR.NO.148) INCLISIRAN SODIUM (LIST 4 SR.NO.148)","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"YANGZHOU AURISCO PHARMACEUTICAL CO","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.50","actualQuantity":"500","unit":"GMS","unitRateFc":"680","totalValueFC":"344786.1","currency":"USD","unitRateINR":"58752","date":"21-May-2025","totalValueINR":"29376000","totalValueInUsd":"344786.1","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"2187525","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":", LTD.NO.28,JIANAN ROAD,HIGH-TECHIN DUSTRIAL DEVELOPMENT ZONE,YANGZHOUC ITY,JIANGSU PROVINCE 225100, P.R. CHINA","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1747765800,"product":"INCLISIRAN SODIUM, BATCH NO INCA-250502 (IMPORT LICENCE. NOSW\/ND\/CT-17\/2025\/000007417INCLISIRAN SODIUM, BATCH NO INCA-250502 (IMPORT LICENCE. NO","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"YANGZHOU AURISCO PHARMACEUTICAL CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"680000","totalValueFC":"206871.7","currency":"USD","unitRateINR":"58752000","date":"21-May-2025","totalValueINR":"17625600","totalValueInUsd":"206871.7","indian_port":"Delhi Air","hs_no":"29349990","bill_no":"2189416","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"NO 28 JIAN AN ROAD HIGH-TECH INDUST RIAL DEVELOPMENT ZONE YANGZHOU CITY JIANGSU PROVINCE 225100 P.R. CHINA","customerAddress":"MUMBAI CENTRAL,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1754073000,"product":"INCLISIRAN (AP1) INCLISIRAN (AP1)","address":"NO.1-1-385\/A, 307,","city":"HYDERABAD, AP.","supplier":"HANGZHOU APEXTIDE BIOMEDICAL TECHNOLOGY CO,LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"INVITRON ADVANCED ANALYTICS PRIVATE LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"1","unit":"GMS","unitRateFc":"5000","totalValueFC":"4958.9","currency":"USD","unitRateINR":"434000","date":"02-Aug-2025","totalValueINR":"434000","totalValueInUsd":"4958.9","indian_port":"Hyderabad Air","hs_no":"29371900","bill_no":"3648442","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"BUILDING 14,YINHAI KECHUANG CENTER NO.501 FUCHENG ROAD XIASHA STREET QIANTANG DISTRICT HANGZHOU CITY CN","customerAddress":"NO.1-1-385\/A, 307,"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1755109800,"product":"INCLISIRAN SODIUM (LIST 4 SR.NO.148) INCLISIRAN SODIUM (LIST 4 SR.NO.148)","address":"MUMBAI CENTRAL,","city":"MUMBAI, MAHARASHTRA.","supplier":"YANGZHOU AURISCO PHARMACEUTICAL CO","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"CIPLA LTD","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"2","unit":"GMS","unitRateFc":"680","totalValueFC":"1376.8","currency":"USD","unitRateINR":"60248","date":"14-Aug-2025","totalValueINR":"120496","totalValueInUsd":"1376.8","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"3879611","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":", LTD.NO.28,JIANAN ROAD,HIGH-TECHIN DUSTRIAL DEVELOPMENT ZONE,YANGZHOUC ITY,JIANGSU PROVINCE 225100, P.R. CHINA","customerAddress":"MUMBAI CENTRAL,"}]
06-Jan-2025
14-Aug-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute Coronary Syndrome.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 04, 2025

blank

01

AIChE Annual Meeting
Not Confirmed
AIChE Annual Meeting
Not Confirmed

Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Acute Coronary Syndrome.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

August 04, 2025

blank

Details:

Leqvio (inclisiran) is a siRNA directed to PCSK9 mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 31, 2025

blank

02

AIChE Annual Meeting
Not Confirmed
AIChE Annual Meeting
Not Confirmed

Details : Leqvio (inclisiran) is a siRNA directed to PCSK9 mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of heterozygous familial hypercholesterolemia.

Product Name : Leqvio

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

July 31, 2025

blank
  • Development Update

Details:

Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.


Lead Product(s): Inclisiran Sodium,Inclisiran

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Oligonucleotide

Sponsor: Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 03, 2025

blank

03

Duke University

Country
arrow
AIChE Annual Meeting
Not Confirmed

Duke University

Country
arrow
AIChE Annual Meeting
Not Confirmed

Lead Product(s) : Inclisiran Sodium,Inclisiran

Therapeutic Area : Undisclosed

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation | Colorado Prevention Center | Mount Sinai Hospital, New York

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

April 03, 2025

blank
  • Development Update

Details:

Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Metabolic Syndrome.


Lead Product(s): Inclisiran Sodium,Inclisiran

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Oligonucleotide

Sponsor: Novartis Pharmaceuticals Corporation

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 10, 2025

blank

04

University of California, San Diego

Country
arrow
AIChE Annual Meeting
Not Confirmed

University of California, San Diego

Country
arrow
AIChE Annual Meeting
Not Confirmed

Details : Inclisiran Sodium is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Metabolic Syndrome.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

March 10, 2025

blank

Details:

Pelacarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atherosclerosis.


Lead Product(s): Pelacarsen,Inclisiran

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 07, 2025

blank

05

AIChE Annual Meeting
Not Confirmed
AIChE Annual Meeting
Not Confirmed

Details : Pelacarsen is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atherosclerosis.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

February 07, 2025

blank

Details:

Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 19, 2024

blank

06

AIChE Annual Meeting
Not Confirmed
AIChE Annual Meeting
Not Confirmed

Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Homozygous Familial Hypercholesterolemia.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

September 19, 2024

blank

Details:

Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 19, 2024

blank

07

AIChE Annual Meeting
Not Confirmed
AIChE Annual Meeting
Not Confirmed

Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heterozygous Familial Hypercholesterolemia.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

September 19, 2024

blank

Details:

Leqvio (inclisiran), the first and only approved siRNA indicated in patients with low or moderate risk of developing atherosclerotic cardiovascular disease and not receiving lipid-lowering therapy.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 28, 2024

blank

08

AIChE Annual Meeting
Not Confirmed
AIChE Annual Meeting
Not Confirmed

Details : Leqvio (inclisiran), the first and only approved siRNA indicated in patients with low or moderate risk of developing atherosclerotic cardiovascular disease and not receiving lipid-lowering therapy.

Product Name : Leqvio

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

August 28, 2024

blank

Details:

Leqvio (inclisiran), approved in over 80 countries, is the first and only approved Small interfering RNA therapy with a successful synthesis of the antisense strand of this drug.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Leqvio

Study Phase: Approved FDFProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 09, 2024

blank

09

AIChE Annual Meeting
Not Confirmed
AIChE Annual Meeting
Not Confirmed

Details : Leqvio (inclisiran), approved in over 80 countries, is the first and only approved Small interfering RNA therapy with a successful synthesis of the antisense strand of this drug.

Product Name : Leqvio

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

July 09, 2024

blank

Details:

Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypercholesterolemia.


Lead Product(s): Inclisiran,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Oligonucleotide

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 26, 2024

blank

10

AIChE Annual Meeting
Not Confirmed
AIChE Annual Meeting
Not Confirmed

Details : Inclisiran is a Oligonucleotide drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypercholesterolemia.

Product Name : Undisclosed

Product Type : Oligonucleotide

Upfront Cash : Inapplicable

April 26, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Leqvio

Inclisiran

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Leqvio

Switzerland
arrow
AIChE Annual Meeting
Not Confirmed

Inclisiran

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 12

2020 Revenue in Millions : 0

Growth (%) : New Launch in 2021

blank

02

Brand Name : Leqvio

Inclisiran

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Leqvio

Switzerland
arrow
AIChE Annual Meeting
Not Confirmed

Inclisiran

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 112

2021 Revenue in Millions : 12

Growth (%) : 833

blank

03

Brand Name : Leqvio

Inclisiran

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Leqvio

Switzerland
arrow
AIChE Annual Meeting
Not Confirmed

Inclisiran

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 355

2022 Revenue in Millions : 112

Growth (%) : 217

blank

04

Brand Name : Leqvio

Inclisiran

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Leqvio

Switzerland
arrow
AIChE Annual Meeting
Not Confirmed

Inclisiran

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2024 Revenue in Millions : 754

2023 Revenue in Millions : 355

Growth (%) : 112

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

read-more
read-more
PharmaCompass
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty